What happened with the CSL share price in FY 2024?

MotleyFool07-05

The CSL Ltd (ASX: CSL) share price couldn't quite match the gains posted by the S&P/ASX 200 Index (ASX: XJO) in the financial year we just said goodbye to. Shares in the ASX 200 biotech stock closed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2449479169?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-05 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449479169","market":"us","top_or_hot":-1,"title":"What happened with the CSL share price in FY 2024?","media":"MotleyFool","content":"<div>\n<p>The CSL Ltd (ASX: CSL) share price couldn't quite match the gains posted by the S&P/ASX 200 Index (ASX: XJO) in the financial year we just said goodbye to. Shares in the ASX 200 biotech stock closed ...</p>\n\n<a href=\"https://www.fool.com.au/2024/07/05/what-happened-with-the-csl-share-price-in-fy-2024/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What happened with the CSL share price in FY 2024?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat happened with the CSL share price in FY 2024?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 03:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2024/07/05/what-happened-with-the-csl-share-price-in-fy-2024/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The CSL Ltd (ASX: CSL) share price couldn't quite match the gains posted by the S&P/ASX 200 Index (ASX: XJO) in the financial year we just said goodbye to. Shares in the ASX 200 biotech stock closed ...</p>\n\n<a href=\"https://www.fool.com.au/2024/07/05/what-happened-with-the-csl-share-price-in-fy-2024/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7506","symbol_name":"金矿股","start_time":0,"source_url":"https://www.fool.com.au/2024/07/05/what-happened-with-the-csl-share-price-in-fy-2024/","article_id":"2449479169","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449479169","pubTimestamp":1720121400,"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"The CSL Ltd (ASX: CSL) share price couldn't quite match the gains posted by the S&P/ASX 200 Index(ASX: XJO) in the financial year we just said goodbye to. Shares in the ASX 200 biotech stock closed ou","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7506":"金矿股","BK7501":"新冠治疗股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7095":"多种金属与采矿","BK4086":"建筑产品","BK7508":"医药生物股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4157":"电子设备和仪器","CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","BK4183":"个人用品","AMI.AU":"AURELIA METALS LTD","MACE":"Mace Security International, Inc.","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7511":"ESG概念"},"translate_title":"2024财年CSL股价发生了什么变化？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":1,"MACE":1,"CSL.AU":1,"CSL":1,"AMI.AU":1},"content_text":"The CSL Ltd (ASX: CSL) share price couldn't quite match the gains posted by the S&P/ASX 200 Index (ASX: XJO) in the financial year we just said goodbye to. Shares in the ASX 200 biotech stock closed out FY 2023 trading for $277.38. On 28 June, the final trading day of FY 2024, shares closed at $295.21 apiece. That put the CSL share price up 6.4% for the full financial year, trailing the 7.8% gains posted by the ASX 200 over this same time.  Of course, that doesn't include the record $3.81 in partly franked dividends that CSL paid out over the year. If we add those back in, the ASX 200 biotech stock gained 7.8% in FY 2024, right in line with the benchmark index. Here's what investors were considering over the past year. Headwinds and tailwinds for the CSL share price Among the headwinds impacting the CSL share price in FY 2024 were the unsatisfactory trial results for its CSL112 product.  CSL112 is intended to reduce the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). But the phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 failed to meet the primary efficacy endpoint of MACE reduction at 90 days. This saw the ASX 200 biotech stock shelve its plans for a near-term regulatory filing. However, CSL's head of R&D, Bill Mezzanotte, highlighted that the study had provided valuable insights and \"enhanced capabilities\". Mezzanotte said on the day:  AEGIS-II is the most ambitious study in our company's history, and we are proud of the quality of the study we delivered and the enhanced capabilities we developed to do so. We plan to apply these capabilities as well as our plasma protein platform to future unmet medical need in cardiovascular and metabolic conditions as well as those in our other strategic therapeutic areas.  The CSL share price closed down 4.8% on the day. February also saw CSL report its half-year financial results. While investors had high expectations and didn't immediately reward the stock, the results were solid. Highlights included an 11% year on year increase in revenue in constant currency to US$8.05 billion. And net profit after tax in constant currency leapt 20% to US$1.94 billion. This saw management up the unfranked interim dividend by 11% to $1.80 per share. As for the nascent FY 2025, the CSL share price is up 0.78% so far in the new financial year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449479169"}